MedTrace Logo

A Trial of Sublingual Misoprostol to Reduce Primary Postpartum Haemorrhage After Vaginal Delivery

NCT05079061 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1300

Last updated 2022-03-03

No results posted yet for this study

Summary

The objective of the randomized controlled study is to compare combination of sublingual misoprostol and routine uterotonics versus routine uterotonics alone on PPH in low risk women after vaginal delivery. The hypothesis is that combination of sublingual misoprostol and routine uterotonics is more effective than routine uterotonics alone in reduction of PPH in low risk women after vaginal delivery.

Conditions

  • Primary Postpartum Hemorrhage
  • Misoprostol
  • Delivery Complication

Interventions

DRUG

Misoprostol

sublingual misoprostol 600 micrograms in addition routine uterotonics at third stage of labour

Sponsors & Collaborators

  • Queen Mary Hospital, Hong Kong

    collaborator OTHER

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Diana Man Ka Chan, MBBS · Department of Obstetrics & Gynaecology, Queen Mary Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-30
Primary Completion
2024-06-30
Completion
2024-06-30
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05079061 on ClinicalTrials.gov